5-fluoro-3-(3-methoxybenzyl)benzo[d]oxazol-2(3H)-one | 1246928-45-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 5-fluoro-3-(3-methoxybenzyl)benzo[d]oxazol-2(3H)-one
• 英文别名: 5-Fluoro-3-[(3-methoxyphenyl)methyl]-1,3-benzoxazol-2-one
• CAS: 1246928-45-9
• 化学式: C₁₅H₁₂FNO₃
• 分子量: 273.264
• InChiKey: LBHIGRIAGJSODQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-fluoro-3-(3-methoxybenzyl)benzo[d]oxazol-2(3H)-one 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 生成 5-fluoro-3-(3-hydroxybenzyl)benzoxazol-2-one
  参考文献：
  名称：

  Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF)

  摘要：

  The cytokine MIF is involved in inflammation and cell proliferation via pathways initiated by its binding to the transmembrane receptor CD74. MIF also exhibits keto-enol tautomerase activity, believed to be vestigial in mammals. Starting from a 1 mu M hit from virtual screening, substituted benzoxazol-2-ones have been discovered as antagonists with IC50 values as low as 7.5 nM in a tautomerase assay and 80 nM in a MIF-CD74 binding assay. Additional studies for one of the potent inhibitors demonstrated that it is not a covalent inhibitor of MIF and that it attenuates MIF-dependent ERK1/2 phosphorylation in human synovial fibroblasts. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.129
• 作为产物：
  描述：

  5-氟-2(3H)-苯并噁唑酮 、 3-甲氧基溴苄 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 5-fluoro-3-(3-methoxybenzyl)benzo[d]oxazol-2(3H)-one
  参考文献：
  名称：

  Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF)

  摘要：

  The cytokine MIF is involved in inflammation and cell proliferation via pathways initiated by its binding to the transmembrane receptor CD74. MIF also exhibits keto-enol tautomerase activity, believed to be vestigial in mammals. Starting from a 1 mu M hit from virtual screening, substituted benzoxazol-2-ones have been discovered as antagonists with IC50 values as low as 7.5 nM in a tautomerase assay and 80 nM in a MIF-CD74 binding assay. Additional studies for one of the potent inhibitors demonstrated that it is not a covalent inhibitor of MIF and that it attenuates MIF-dependent ERK1/2 phosphorylation in human synovial fibroblasts. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.129

文献信息

• MIF modulators
  申请人：YALE UNIVERSITY

  公开号：US10202343B2

  公开（公告）日：2019-02-12

  The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.

  本发明提供了新型杂环化合物、药物组合物和治疗方法，可调节 MIF 的表达水平，治疗与 MIF 表达水平过高或过低有关的疾病。
• US9643922B2
  申请人：——

  公开号：US9643922B2

  公开（公告）日：2017-05-09
• [EN] COMPOUNDS AND METHODS FOR TREATING COPD AND/OR LUNG FIBROSIS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT D'UNE MPOC ET/OU D'UNE FIBROSE PULMONAIRE
  申请人：UNIV YALE

  公开号：WO2020123610A1

  公开（公告）日：2020-06-18

  In various aspects and embodiments the invention provides methods for the treatment of a MIF-mediated disease. In one aspect, the invention provides a method of treating a fibrotic disease in a male subject in need thereof, the method comprising administering to the male subject an effective amount of at least one MIF agonist. In various embodiments, the fibrotic disease is lung fibrosis. In another aspect, the invention provides a method of treating chronic obstructive pulmonary disease (COPD) in a female subject in need thereof, the method comprising administering to the female subject an effective amount of at least one MIF agonist. In various embodiments, the COPD is emphysema type COPD.
• [EN] METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF<br/>[FR] MÉTHODES DE TRAITEMENT DE LA SPONDYLARTHRITE OU DE SES SYMPTÔMES
  申请人：[en]UNIVERSITY HEALTH NETWORK

  公开号：WO2022087719A1

  公开（公告）日：2022-05-05

  Provided are methods of treating SpA, uses for treating SpA and compositions for treating SpA. The methods involve administering a MIF inhibitor to a subject in need thereof. The MIF inhibitor can be a compound or an anti-MIF antibody.